19 Results

People

  1. Drilon
    Drilon
  2. Hechtman
    Hechtman
  3. Hyman
    Hyman
  4. Benayed
    Benayed
  5. Ladanyi
    Ladanyi
  6. Schram
    Schram
  7. Rosen
    Rosen
  8. Scaltriti
    Scaltriti
  9. Taylor
    Taylor
  10. Frosina
    Frosina

Groups

  1. Department of Medicine (19)
  2. Solid Tumor Oncology Division (19)
  3. Thoracic Oncology (19)
  4. GSK Faculty (16)
  5. Early Drug Development Service (15)
  6. Human Oncology and Pathogenesis Program (14)
  7. Tow Center for Developmental Oncology (TCDO) (12)
  8. Sloan Kettering Institute Postdocs (9)
  9. Gynecologic Medicine Service (8)
  10. Breast Medicine Service (3)
  1. "Department of Medicine"
  2. "Journal article"
  3. "Alexander Drilon"
  4. "Jaclyn Hechtman"
Formats
  1. Journal Article (19)
Groups
  1. Department of Medicine (19)
  2. Solid Tumor Oncology Division (19)
  3. Thoracic Oncology (19)
  4. GSK Faculty (16)
  5. Early Drug Development Service (15)
  6. Human Oncology and Pathogenesis Program (14)

More Groups

People
  1. Alexander Drilon (19)
  2. Jaclyn Hechtman (19)
  3. David Hyman (13)
  4. Marc Ladanyi (12)
  5. Ryma Benayed (11)
  6. Alison Schram (8)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (3)
  4. 2020 (3)
  5. 2019 (3)
  6. 2018 (4)

More Years

Publications
  1. Clinical Cancer Research (4)
  2. Annals of Oncology (3)
  3. JCO Precision Oncology (3)
  4. American Journal of Surgical Pathology (2)
  5. Cancer Discovery (2)
  6. Cancer Genetics (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (3)
  3. Oxford University Press (3)
  4. Elsevier Inc. (2)
  5. Lippincott Williams & Wilkins (2)
  6. Massachusetts Medical Society (1)

More Publishers

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation
    Journal Article

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D. A.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benayed, R.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib
    Journal Article

    Rudzinski, E. R.; Hechtman, J.; Roy-Chowdhuri, S.; Rudolph, M.; Lockwood, C. M.; Silvertown, J.; Wierzbinska, J.; Shen, K.; Norenberg, R.; Nogai, H.; more...
    Cancer Genetics (2022)

    Fulltext@MSK | Save
  • A performance comparison of commonly used assays to detect RET fusions
    Journal Article

    Yang, S. R.; Aypar, U.; Rosen, E. Y.; Mata, D. A.; Benayed, R.; Mullaney, K.; Jayakumaran, G.; Zhang, Y.; Frosina, D.; Drilon, A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib
    Journal Article

    Rosen, E. Y.; Johnson, M. L.; Clifford, S. E.; Somwar, R.; Kherani, J. F.; Son, J.; Bertram, A. A.; Davare, M. A.; Gladstone, E.; Ivanova, E. V.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • TRK XDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Journal Article

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arruabarrena-Aristorena, A.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
    Journal Article

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • NTRK fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls
    Journal Article

    Solomon, J. P.; Linkov, I.; Rosado, A.; Mullaney, K.; Rosen, E. Y.; Frosina, D.; Jungbluth, A. A.; Zehir, A.; Benayed, R.; Drilon, A.; more...
    Modern Pathology (2020)

    Fulltext@MSK | Save
  • Real-world outcomes of an automated physician support system for genome-driven oncology
    Journal Article

    Tao, J. J.; Eubank, M. H.; Schram, A. M.; Cangemi, N.; Pamer, E.; Rosen, E. Y.; Schultz, N.; Chakravarty, D.; Philip, J.; Hechtman, J. F.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors
    Journal Article

    Rosen, E. Y.; Schram, A. M.; Young, R. J.; Schreyer, M. W.; Hechtman, J. F.; Shu, C. A.; Ku, N. C.; Hyman, D. M.; Drilon, A.
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save